Everything below concerns LY3437943. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
== Principles of operation == ELSDs analyze solutes eluting out of the chromatographic column, both in LC and SFC. As the eluent exits the column's outlet into the detector inlet, it is mixed with an inert carrier gas (usually nitrogen) and forced through a nebulizer, which separates the liquid into fine aerosolized droplets. These droplets then pass into a heated drift tube, where the mobile phase solvent is evaporated off. As the mobile phase evaporates, the droplets become smaller and smaller until all that is left is minute particles of dried analyte. These particles are pushed through the drift tube by the carrier gas to the detection region. In this region, a beam of light crosses the column of analyte and the scattering of light is measured by a photodiode or photomultiplier tube. The detector's output is non-linear across more than one order of magnitude and proper calibration is required for quantitative analysis.
== Awards and accolades == New York Magazine Gael Greene's Restaurant of the Year – Mesa Grill (1992) French Culinary Institute Outstanding Graduate Award (1993) International Association of Culinary Professionals Award for Design – Bobby Flay's Bold American Food (1995) Four-time Daytime Emmy Award winner: Outstanding Service Show Host – Boy Meets Grill (2005) Best Culinary Program – Grill It! With Bobby Flay (2009) Outstanding Culinary Host – Bobby Flay's Barbecue Addiction (2014) Outstanding Culinary Host – Bobby Flay's Barbecue Addiction (2015) Three-time James Beard Foundation Award winner: Rising Star Chef of the Year (1993) National Television Food Show Award – Bobby Flay Chef Mentor (2005) Who's Who of Food & Beverage in America (2007) Culinary Hall of Fame Induction (2015) Star on Hollywood Walk of Fame (2015)
== History == Electron-capture dissociation (ECD) was developed in 1998 to fragment large proteins for mass spectrometric analysis. Because ECD requires a large amount of near-thermal electrons (<0.2eV), originally it was used exclusively with Fourier transform ion cyclotron resonance mass spectrometry (FTICR), the most expensive form of MS instrumentation. Less costly options such as quadrupole time-of-flight (Q-TOF), quadrupole ion trap (QIT) and linear quadrupole ion trap (QLT) instruments used the more energy-intensive collision-induced dissociation method (CID), resulting in random fragmentation of peptides and proteins. In 2004 Syka and Coon et al. announced the creation of ETD, a dissociation method similar to ECD, but using a low-cost, widely available commercial spectrometer. The first ETD experiments were run on a QLT mass spectrometer with an electrospray ionization (ESI) source.
=== John-Daniel Stern === John-Daniel "JD" Stern (Adain Bradley) is Harper's estranged twin brother, who disappeared from her life when the two were teenagers. In series 2, Harper tracks down her brother to Berlin, where he works as a line cook. The two spend the night at a club, and the next morning, JD relapses on his meth addiction. The two have a vicious argument over their childhood growing up with an abusive mother; JD reveals he ran away in part due to Harper exacerbating the pressure their mother put on him to be a star tennis player, but Harper maintains that she too escaped a traumatic upbringing. Harper begs JD to come home with her, but rebuffs her, branding his sister a selfish narcissist who was complicit in the abuse he suffered. Harper is left deeply shaken by the encounter. In series 4, JD calls Harper to tell her that their mother died in a freak accident, having fallen down the stairs while collecting an Amazon delivery. Harper struggles to grieve her mother's death given her traumatic childhood, as well as her preoccupation with her work.
The announcement of the regulations which brought down the Wall took place at an hour-long press conference led by Günter Schabowski, the outgoing party leader in East Berlin and top party spokesman as Secretary for Information, beginning at 18:00 CET on 9 November and broadcast live on East German television and radio. Schabowski was joined by Minister of Foreign Trade Gerhard Beil and Central Committee members Helga Labs and Manfred Banaschak. Topics of the press conference included the results of votes at the Central Committee meeting, the surprising removal of SED Bezirk First Secretaries Hans-Joachim Böhme and Werner Walde, the SED's electoral and press reform plans and the new travel regulations. Schabowski had not been involved in the discussions about the new regulations and had not been fully updated. Shortly before the press conference, he was handed a note from Krenz announcing the changes, but given no further instructions on how to handle the information. The text stipulated that East German citizens could apply for permission to travel abroad without having to meet the previous requirements for those trips, and also allowed for permanent migration between all border crossings—including those between East and West Berlin. At 18:53, near the end of the press conference, ANSA's Riccardo Ehrman asked if the draft travel law of 6 November was a mistake.
Sources: en.wikipedia.org
Upon his return to the United States in 1973, he became deputy commander for operations at George Air Force Base, California. In 1974 he was assigned as vice commander at Nellis Air Force Base, Nevada, where he flew as an aggressor pilot. He then transferred to Tactical Air Command at Langley Air Force Base in 1975 as director of fighter and reconnaissance operations. In 1976 and 1977 he was assistant to the commander there. Chain became the military assistant to the Secretary of the Air Force in 1978. He then served as deputy director of plans at Air Force headquarters until 1980, when he became director of operations. Chain was assigned as assistant deputy chief of staff for plans and operations in 1981 and became deputy chief of staff for plans and operations in 1982. He served as director of the Bureau of Political-Military Affairs for the Department of State from 1984 until 1985, when he became chief of staff for Supreme Headquarters Allied Powers Europe in Belgium. On July 1, 1985, Chain was promoted to general. In 1986 he became commander in chief of Strategic Air Command, where he oversaw the LGM-118A Peacekeeper operations for the Reagan Administration. He retired from the military on January 31, 1991.
=== Scientific research === Liquid argon is used as the target for neutrino experiments and direct dark matter searches. The interaction between the hypothetical WIMPs and an argon nucleus produces scintillation light that is detected by photomultiplier tubes. Two-phase detectors containing argon gas are used to detect the ionized electrons produced during the WIMP–nucleus scattering. As with most other liquefied noble gases, argon has a high scintillation light yield (about 51 photons/keV), is transparent to its own scintillation light, and is relatively easy to purify. Compared to xenon, argon is cheaper and has a distinct scintillation time profile, which allows the separation of electronic recoils from nuclear recoils. On the other hand, its intrinsic beta-ray background is larger due to 39Ar contamination, unless one uses argon from underground sources, which has much less 39Ar contamination. Most of the argon in Earth's atmosphere was produced by electron capture of long-lived 40K (40K + e− → 40Ar + ν) present in natural potassium within Earth. The 39Ar activity in the atmosphere is maintained by cosmogenic production through the knockout reaction 40Ar(n,2n)39Ar and similar reactions. The half-life of 39Ar is only 269 years. As a result, the underground Ar, shielded by rock and water, has much less 39Ar contamination. Dark-matter detectors currently operating with liquid argon include DarkSide, WArP, ArDM, microCLEAN and DEAP.
Dipeptidyl peptidase-4 inhibitors inhibit dipeptidyl peptidase-4 and thus reduce glucagon and blood glucose levels. DPP-4 inhibitors combined with metformin include a sitagliptin/metformin combination (Janumet), a saxagliptin/metformin combination (Kombiglyze XR, Komboglyze), and an alogliptin/metformin combination (Kazano, Vipdomet). Linagliptin combined with metformin hydrochloride is sold under the brand name Jentadueto. As of August 2021, linagliptin/metformin is available as a generic medicine in the US.
Nicotine was originally isolated from the tobacco plant in 1828 by chemists Wilhelm Heinrich Posselt and Karl Ludwig Reimann from Germany, who believed it was a poison. Its chemical empirical formula was described by Melsens in 1843, its structure was discovered by Adolf Pinner and Richard Wolffenstein in 1893, and it was first synthesized by Amé Pictet and A. Rotschy in 1904. Nicotine is named after the tobacco plant Nicotiana tabacum, which in turn is named after the French ambassador in Portugal, Jean Nicot de Villemain, who sent tobacco and seeds to Paris in 1560, presented to the French King, and who promoted their medicinal use. Smoking was believed to protect against illness, particularly the plague. However, the "holy herb", tobacco, had first reached Europe by the early 1530s, brought by Spanish explorers. Following its introduction, tobacco rapidly gained popularity in Europe for its stimulating effects, fueled by nicotine's addictive and pharmacological properties and tobacco's widespread embrace as a cure-all. By the early 17th century, this allure fueled its mercilessly laborious cultivation as a cash crop in the Virginia colonies, where John Rolfe's introduction in 1612 rescued Jamestown from economic collapse and famine, transforming it into a prosperous export hub with over 20,000 pounds shipped by 1619 and laying the groundwork for transatlantic trade.
Sources: en.wikipedia.org
Diffusion force caused by concentration gradient—all particles including ions diffuse from higher concentration to lower. Electrostatic force caused by electrical potential gradient—cations like protons H+ diffuse down the electrical potential, anions in the opposite direction. These two gradients together can be expressed as an electrochemical gradient, providing energy for abiogenic synthesis. The proton motive force measures the potential energy stored as proton and voltage gradients across a membrane (differences in proton concentration and electrical potential). The surfaces of mineral particles inside deep-ocean hydrothermal vents have catalytic properties similar to those of enzymes, and can create simple organic molecules, such as methanol (CH3OH) and formic, acetic, and pyruvic acids out of the dissolved CO2 in the water, if driven by an applied voltage or by reaction with H2 or H2S. Starting in 1981, researchers proposed that life might have started at hydrothermal vents, that spontaneous chemistry in the Earth's crust driven by rock–water interactions at disequilibrium thermodynamically underpinned life's origin, and that the founding lineages of the archaea and bacteria were H2-dependent autotrophs that used CO2 as their terminal acceptor in energy metabolism. In 2016, Martin suggested that the LUCA "may have depended heavily on the geothermal energy of the vent to survive". That same year, RNA was produced in synthetic alkaline hydrothermal chimneys simulating deep-sea vents. Researchers were able to generate RNA oligomers of up to 4 units in length.
=== Non-modifiable === Scandinavian or Northern European ancestry; Dupuytren's has been called the "Viking disease", though it is also widespread in some Mediterranean countries, e.g., Spain and Bosnia. Dupuytren's is uncommon among groups including Chinese and Africans. In June 2023 a study found that gene variants that were inherited from Neanderthals dramatically increased the odds of developing the condition Male sex; men are 80% more likely to develop the condition Age of 50 or over (5% to 15% of men in that group in the US); the likelihood of getting Dupuytren's disease increases with age A family history (60% to 70% of those affected have a genetic predisposition to Dupuytren's contracture)
== History of the taxonomy == Prior to 1993, the family Conidae contained only Conus species. In 1993 significant taxonomic changes were proposed by Taylor, et al.,: the family Conidae was redefined as several subfamilies. The subfamilies included many subfamilies that had previously been classified in the family Turridae, and the Conus species were moved to the subfamily Coninae. In further taxonomic changes that took place in 2009 and 2011, based upon molecular phylogeny (see below), the subfamilies that were previously in the family Turridae were elevated to the status of families in their own right. This left the family Conidae once again containing only those species that were traditionally placed in that family: the cone snail species.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.